This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Tilray Brands, Inc. (TLRY) Registers a Bigger Fall Than the Market: Important Facts to Note
by Zacks Equity Research
Tilray Brands, Inc. (TLRY) closed the most recent trading day at $1.19, moving 2.46% from the previous trading session.
Green Thumb Launches $50M Buyback: Time to Get Bullish on the Stock?
by Sundeep Ganoria
GTBIF launches a $50 million share buyback program, signaling confidence in long-term growth despite market and pricing pressures.
Cannabis Stock CRLBF Gains 25% in a Month: Time to Buy, Sell or Hold?
by Sundeep Ganoria
CRLBF surges 25% this month on reform hopes, but revenue declines, margin pressure and stiff competition cloud its outlook.
Tilray Brands, Inc. (TLRY) Stock Falls Amid Market Uptick: What Investors Need to Know
by Zacks Equity Research
In the closing of the recent trading day, Tilray Brands, Inc. (TLRY) stood at $1.12, denoting a -5.88% move from the preceding trading day.
Cannabis Stock CRON Trades Near 52-Week High: How to Play
by Sundeep Ganoria
Cronos trades near its 52-week high as international growth boosts sales, but losses and stiff competition weigh on its outlook.
Tilray Brands, Inc. (TLRY) Dips More Than Broader Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Tilray Brands, Inc. (TLRY) closed at $1.25, marking a -9.42% move from the previous day.
Tilray Brands, Inc. (TLRY) Stock Falls Amid Market Uptick: What Investors Need to Know
by Zacks Equity Research
The latest trading day saw Tilray Brands, Inc. (TLRY) settling at $1.37, representing a -5.52% change from its previous close.
Tilray Brands, Inc. (TLRY) Declines More Than Market: Some Information for Investors
by Zacks Equity Research
In the closing of the recent trading day, Tilray Brands, Inc. (TLRY) stood at $1.03, denoting a -12.71% move from the preceding trading day.
Cannabis ETFs Soar as Trump Mulls Over Marijuana Reclassification
by Sweta Killa
Cannabis ETFs like WEED, CNBS and MJ surge after Trump confirmed that his administration is weighing marijuana's move from Schedule I to Schedule III.
Can Cannabis Stocks Reverse Their Prolonged Downtrend?
by Sundeep Ganoria
Cannabis stocks like TLRY and GTBIF remain deep in years-long slump, but U.S. federal reform or global expansion could ignite a long-awaited rebound.
Aurora Cannabis Pre-Q1 Earnings Analysis: Buy, Sell or Hold the Stock?
by Zacks Equity Research
ACB's global medical cannabis momentum stays strong, but near-term regulatory headwinds might have limited Q1 revenue upside.
Should You Buy, Hold or Sell TLRY Stock Post Q4 Earnings Release?
by Sundeep Ganoria
Tilray posts record non-cannabis revenues in fiscal 2025, but Q4 sales slip as cannabis weakness pressures overall results.
Tilray Brands, Inc. (TLRY) Q4 Earnings Beat Estimates
by Zacks Equity Research
Tilray Brands (TLRY) delivered earnings and revenue surprises of +166.67% and -6.46%, respectively, for the quarter ended May 2025. Do the numbers hold clues to what lies ahead for the stock?
Cannabis Operator CRLBF Plans California Exit: How to Play the Stock?
by Sundeep Ganoria
Cresco plans to exit California, citing tough market dynamics, as it sharpens focus on high-margin growth markets.
Tilray Brands, Inc. (TLRY) Stock Slides as Market Rises: Facts to Know Before You Trade
by Zacks Equity Research
Tilray Brands, Inc. (TLRY) closed at $0.74 in the latest trading session, marking a -6.34% move from the prior day.
Exploring Analyst Estimates for Tilray Brands (TLRY) Q4 Earnings, Beyond Revenue and EPS
by Zacks Equity Research
Besides Wall Street's top-and-bottom-line estimates for Tilray Brands (TLRY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended May 2025.
Tilray Brands, Inc. (TLRY) Beats Stock Market Upswing: What Investors Need to Know
by Zacks Equity Research
In the latest trading session, Tilray Brands, Inc. (TLRY) closed at $0.61, marking a +1.21% move from the previous day.
Tilray Brands, Inc. (TLRY) Declines More Than Market: Some Information for Investors
by Zacks Equity Research
In the closing of the recent trading day, Tilray Brands, Inc. (TLRY) stood at $0.58, denoting a -8.88% move from the preceding trading day.
Cannabis Stock Cresco Labs Plunges 24% YTD: Time to Sell or Hold?
by Sundeep Ganoria
CRLBF is down 24% YTD as U.S.-only exposure, falling margins and tighter regulations weigh on its cannabis business.
Phibro (PAHC) Soars 6.8%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Phibro (PAHC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Here's Why Tilray Brands, Inc. (TLRY) Fell More Than Broader Market
by Zacks Equity Research
In the most recent trading session, Tilray Brands, Inc. (TLRY) closed at $0.5, indicating a -6.55% shift from the previous trading day.
Tilray Brands, Inc. (TLRY) Stock Declines While Market Improves: Some Information for Investors
by Zacks Equity Research
Tilray Brands, Inc. (TLRY) reached $0.4 at the closing of the latest trading day, reflecting a -2.84% change compared to its last close.
Cannabis Operator Curaleaf Plunges 46% YTD: Time to Sell or Hold?
by Sundeep Ganoria
CURLF dives 46% YTD as domestic headwinds outweigh global growth; is it time to cash out or wait for a rebound?
Could the New Federal Bill Derail the U.S. Hemp Industry?
by Sundeep Ganoria
A proposed federal bill could upend the U.S. hemp market, threatening CBD and Delta-8 products now sold nationwide.
Why Tilray Brands, Inc. (TLRY) Dipped More Than Broader Market Today
by Zacks Equity Research
Tilray Brands, Inc. (TLRY) closed at $0.38 in the latest trading session, marking a -9.07% move from the prior day.